Roche said it will launch a Phase 3 trial testing prasinezumab, an anti-alpha-synuclein antibody, as a potential treatment for early-stage Parkinson’s disease. The decision follows data from two Phase 2 trials showing prasinezumab had potential clinical efficacy at slowing motor symptom progression and reducing motor complications as an add-on…
A new clinical program will use ibogaine, a naturally occurring psychedelic, to treat neurodegenerative conditions including Parkinson’s disease. Ambio Life Sciences, which hosts other ibogaine programming and participates in scientific research about the drug, soft-launched the program in February. It is the first of its kind in the…
Aging interferes with the way neurons, or nerve cells, respond to stress, making them more susceptible to damage and more likely to contribute to neurodegenerative diseases such as Parkinson’s, according to a study in cells and brain tissue. “It’s the neuronal equivalent of being so stressed that you catch…
Researchers in Texas have discovered a promising therapeutic target for neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease. Using a mouse model of Alzheimer’s disease, they found that blocking the stress sensor GADD45G in astrocytes, which are star-shaped cells that support neurons, reduced the buildup of toxic proteins…
CAP-003, a gene therapy for Parkinson’s disease associated with GBA mutations, has been cleared by the U.S. Food and Drug Administration (FDA) for testing in clinical trials. These mutations are the most common genetic risk factor for Parkinson’s. With this FDA clearance, developer Capsida Biotherapeutics plans to launch a…
Parkinson’s disease patients in a pilot study testing the effects of equine-associated therapy report that they enjoy working with horses, while researchers say they hope results from the program will provide evidence of its benefits. “We hope to show there is effectiveness in this type of treatment to apply…
Stimulating nerve cells in a region of the brain involved in processing sound and emotions may help ease motor symptoms such as those caused by Parkinson’s disease, without unwanted side effects on emotional response, according to a study in rats. While it’s still early to understand if these…
Casma Therapeutics said it will develop CSM-101 as a potential disease-modifying oral treatment for people with Parkinson’s disease and Gaucher disease. CSM-101 is a first-in-class small molecule designed to activate the calcium channel TRPML1, a key regulator of lysosomal function and autophagy, a process in which cells deliver…
People with Parkinson’s disease who have mild cognitive changes before deep brain stimulation (DBS) are not more likely to develop dementia later in life than those whose cognitive function was normal before the surgery, a Danish study has found. Instead, the researchers observed that dementia was more likely…
Rune Labs and the Parkinson’s Foundation are partnering on a clinical program to identify genetic and digital biomarkers showing how genetics and daily symptoms are connected in people with Parkinson’s disease, with the aim of speeding diagnosis, improving clinical trial design, and supporting the development of more targeted treatments. The…
Get regular updates to your inbox.
